Work

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5080

Authors: Michael B. Atkins, Igor Puzanov, Elizabeth R. Plimack, Mayer N. Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Jamal Christo Tarazi, William Duggan, Rodolfo F. Perini, Kathrine C. Fernandez, Toni K. Choueiri

Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Vanderbilt University Medical Center, Fox Chase Cancer Center, Moffitt Cancer Center, Beth Israel Deaconess Medical Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Roswell Park Comprehensive Cancer Center, Pfizer (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W3030988078

Cites:

Cited by: 1

Related to: 10